IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer
Conclusion Adoptive transfer of ACTIL −15 cells in a mouse model of GC and in patients with advanced GC treated with S1 + oxaliplatin improved survival rates in both, with an acceptable safety profile. (Source: Investigational New Drugs)
Source: Investigational New Drugs - August 13, 2021 Category: Drugs & Pharmacology Source Type: research
In vitro selection of DNA aptamers against human osteosarcoma
Conclusions. These results suggest that OS-7.9 could recognize a common protein expressed in these cancer cells, possibly becoming a potential molecular probe for early diagnosis and targeted therapies for metastatic disease. Moreover, to the best of our knowledge, this was the first attempt to generate a DNA aptamer (OS-7.9 aptamer) against the MG-63-cell line by cell-SELEX. (Source: Investigational New Drugs)
Source: Investigational New Drugs - August 12, 2021 Category: Drugs & Pharmacology Source Type: research
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition
Conclusion. In this prospective analysis of inoperable stage III NSCLC patients treated with definitive CRT combined with concurrent and/or sequential CPI, significantly shorter PFS and eMFS were observed in patients with initial PTV ≥ 900ccm. (Source: Investigational New Drugs)
Source: Investigational New Drugs - August 5, 2021 Category: Drugs & Pharmacology Source Type: research
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer
Conclusion. Preliminary results revealed that pioglitazone adjunacy with celecoxib may be an effective chemo-preventive agent against NNK induce NSCLC. (Source: Investigational New Drugs)
Source: Investigational New Drugs - August 2, 2021 Category: Drugs & Pharmacology Source Type: research
Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors
Conclusions. This study did not identify statistically significant associations between NTRK fusion and PFS. Nonsignificant trends estimated increases in the risk of progression or death events for patients with NTRK fusions when compared to matched controls. Our findings help illuminate the influence of NTRK fusions on the natural history of a variety of solid tumors. (Source: Investigational New Drugs)
Source: Investigational New Drugs - August 2, 2021 Category: Drugs & Pharmacology Source Type: research
